Investment case
Otsuka Holdings Co., Ltd. (ADR)
OTIC · 5 developments mapped · last assessed 2026-09-19
Market Ontology has mapped 5 macro, policy, and market developments to Otsuka Holdings Co., Ltd. (ADR) since 2026-09-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for OTIC yet, so no modelled value is shown. The OTIC valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run OTIC on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Main threat
Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions
Increased competitive pressure and potential market share erosion for their long-acting injectable antipsychotics (e.g., Abilify Maintena) due to UZEDY's demonstrated superior outcomes and cost profile.
· Moves sales forecasts for competing long acting injectables, market share in antipsychotic segment
- Open question
Teva real-world data demonstrates UZEDY reduces emergency care and medical costs
Increased competitive pressure on Otsuka's long-acting injectable schizophrenia treatments (e.g., Abilify Maintena) due to Teva's UZEDY demonstrating superior real-world outcomes and cost-effectiveness, potentially leading to slower growth or market share erosion.
· Moves abilify maintena sales growth rate, market share in long acting injectables for schizophrenia
What changed, by assumption
- 2026-09-19Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions
- 2026-09-19Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity
- 2026-09-19Teva real-world data demonstrates UZEDY reduces emergency care and medical costs
- 2026-09-19Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity
- 2026-09-19Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-19 | Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity | Bearish | 1-3m | 0.30 |
| 2026-09-19 | Teva real-world data demonstrates UZEDY reduces emergency care and medical costs | Bearish | 3-12m | 0.30 |
| 2026-09-19 | Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity | Bearish | 3-12m | 0.30 |
| 2026-09-19 | Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions | Bearish | 3-12m | 0.40 |
| 2026-09-19 | Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables | Bearish | 1-3m | 0.30 |